marketshareAI
Theme

Avacta Group

AVCTHealthcare
78.68GBX
-0.16%
Market Cap
341.18M
Volume
436.76k
17% of avg
P/E Ratio
-8.32
EPS (TTM)
-9.46
Beta
-0.19
Day Range
78.00p - 80.00p
52 Week Range
26.00p78.68p83.20p
78.68p

Upcoming Events

December 17, 2025
Presentation of Faridoxorubicin Phase 1b trial data
High Impact Event
Early Q1 2026
Phase 1 trial of AVA6103 to begin
High Impact Event
Q1 2026
Planned initiation of FAP-EXd (AVA6103) Phase Ia trial
High Impact Event
Early 2026
Phase 1 trial for FAP-EXd (AVA6103) anticipated to begin
High Impact Event
Early Q2 2026
Planned start of Phase 2 trials for FAP-Dox in salivary gland cancer and triple negative breast cancer
High Impact Event
June 30, 2026
Potential data readouts for faridoxorubicin (FAP-Dox, AVA6000) Phase 1b trials in triple negative breast cancer
High Impact Event
AVCT
NEUTRAL

Avacta Provides Update on Faridoxorubicin Phase 1b Trial

The life sciences company announces preliminary data from a Phase 1b trial for its cancer therapy candidate.

AVCT
NEUTRAL

Avacta Completes Placing and TVR

The healthcare company has completed a placing and transaction to increase its share capital.

AVCT
NEUTRAL

Avacta presents promising preclinical data for dual payload cancer therapy

The biotechnology company has presented preclinical data on its innovative dual payload cancer therapy, which aims to overcome resistance and maximize tumor control.

AVCT
NEUTRAL

Avacta Group Announces Investor Presentation on Pre|CISION® Platform

The biopharmaceutical company will present data on its pre|CISION® oncology delivery platform at an investor event.

AVCT
NEUTRAL

Avacta Raises £16 Million Through Equity Fundraise

The biotechnology company has raised £16 million through a discounted equity placing to fund the advancement of its oncology pipeline.

AVCT
NEUTRAL

Avacta Presents Positive Phase 1a Data for Faridoxorubicin

The biopharmaceutical company has presented positive Phase 1a data for its lead program, faridoxorubicin, demonstrating favorable safety and tolerability as well as promising efficacy in certain cancer types.

AVCT
NEUTRAL

Avacta Presents Groundbreaking Dual Payload PDC Data at EORTC-NCI-AACR

The biopharmaceutical company announces it will present data on its first dual-payload PDC at an upcoming cancer therapeutics conference, showcasing its innovative oncology delivery platform.

AVCT
NEUTRAL

Avacta Reports Progress in Clinical Trials Amid Financial Challenges

The clinical-stage biotech firm reports progress in its cancer therapy trials, but faces financial headwinds with flat revenue and decreasing net assets.

AVCT
NEUTRAL

Avacta Group Provides Interim Results Update and ESMO Congress Details

The biotechnology company provides details on its upcoming interim results announcement and a change in the presentation at the ESMO Congress.

AVCT
NEUTRAL

Avacta's pre|CISION® Platform Shortlisted for AIM Technology of the Year Award

The biotechnology company has been shortlisted for a prestigious industry award, recognizing the potential of its innovative pre|CISION® platform.